Development of new medicinal products for the treatment of ulcerative colitis

  • Email
  • Help
Current effective version

Adopted guideline

Currently under revision - see below

Reference numberCHMP/EWP/18463/06
Published24/01/2008
Effective from01/08/2008
KeywordsDrug evaluation, drug approval, ulcerative colitis
DescriptionThis document provides guidance for the evaluation of new medicinal products in the treatment of ulcerative colitis. It clarifies the requirements for clinical documentation needed to support a marketing authorisation, the selection of patients, the recommended methods to assess efficacy, the strategy and design of clinical trials, safety aspects and overall strategy of development.


Document history

Revision 1

In progess

Draft guideline

 

Concept paper

 

Concept paper

Published: 01/08/2016
Deadline for comments: 31/01/2017

 

Published: 01/10/2014

 

Published: 14/11/2012

First version 

Current version

Adopted guideline

 

Overview of comments

 

Draft guideline

In operation: 01/08/2008–present

 

Published: 21/02/2008

 

Published: 16/11/2006


Related content


How helpful is this page?

Average rating:

 Based on 1 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
1 ratings
    

Tell us more